Home » PR Pharmaceuticals' PulmoLAR Gets Orphan-Drug Status
PR Pharmaceuticals' PulmoLAR Gets Orphan-Drug Status
May 23, 2005
The FDA has granted orphan-drug designation to PulmoLAR, PR Pharmaceuticals' lead compound for the treatment of pulmonary arterial hypertension (PAH).
Preclinical experiments and in vitro studies have demonstrated that PulmoLAR (2-methoxyestradiol) addresses many of the pathological processes associated with PAH, the firm said. PR Pharmaceuticals plans to file an investigational new drug application and initiate Phase I studies in 2005 to support continued development of the drug.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct